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Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as
advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial
results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials
have been presented, some with potential important implications for future treatments. We provide here an overview of these
important results and their integration into routine clinical practice.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01474-y
HIGHLIGHTS IN OESOPHAGOGASTRIC CANCER
EORTC oesophagogastric task force: Elizabeth Smyth and
Dorothea Wagner
ASCO-GI 2021 provided some interesting results in the areas of
targeted therapy, and immunotherapy for patients with advanced
gastric cancer. The first pathway addressed was the fibroblast
growth factor receptor (FGFR) pathway, a potential therapeutic
target which is known to stimulate angiogenesis, transformation
and proliferation of tumour cells [1]. Bemarituzumab is a first-in
class humanised IgG1 monoclonal antibody, which selectively
binds to FGFR2b. On the basis of a favourable safety profile and an
18% confirmed overall response rate (RR) in a phase I-study in pre-
treated patients with gastroesophageal cancer, FIGHT
(NCT03343301), a global, double-blind, randomised phase II trial
evaluating Bemarituzumab was conducted in chemo naive
patients with HER2 negative, advanced or metastatic GC and
centrally confirmed either FGFR2b overexpression by immunohis-
tochemistry or -amplification by circulating tumour DNA [2]. The
design of this trial was changed from phase III to a randomised
phase II while ongoing. One hundred and fifty-five patients were
randomised 1:1 to mFOLFOX6 with either bemarituzumab 15mg/
kg or placebo every 2 weeks plus 7.5 mg/kg bemarituzumab or
placebo on day 8. The primary endpoint was progression-free
survival (PFS), among the secondary endpoints were overall
survival (OS) and ORR. Of 910 patients tested, 30% were FGFR2B
positive. With a median PFS of 9.5 vs. 7.4 months (hazard ratio [HR]
0.68, 95% confidence interval [CI], 0.44–1.04, p= 0.07) Fig. 1, and a
median OS not reached (NR) in patients treated with bemaritu-
zumab vs. 12.9 months (HR 0.58, 95% CI, 0.35–0.95, p= 0.03), both
endpoints were met. Stomatitis and corneal adverse events (AEs)
were higher in patients treated with bemarituzumab. While this
proof-of-concept study clearly demonstrates activity of FGFR2b
targeting in gastric cancer, longer follow-up and confirmation of
these findings in a phase III trial are necessary to fully characterise
the magnitude of the patient benefit from this treatment [3].
HER2-directed therapy was also in the spotlight at GI ASCO 2021
with promising signs of efficacy for a novel HER2-targeted
bispecific antibody zanidatamab in gastric cancer. Zanidatamab
monotherapy showed a RR of 38%, and was also safely combined
with chemotherapy [4]. Together with trastuzumab deruxtecan
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and margetuximab, zanidatamab appears to be a good candidate
for integration with chemotherapy or immunotherapy in future for
HER2 positive gastric cancer patients [5, 6]. Considering HER2-
directed therapy plus immunotherapy, the results of triplet
treatment of chemotherapy, trastuzumab and pembrolizumab in
first-line advanced gastric cancer in the PANTERA study were also
presented at ASCO-GI 2021 [7]. Radiological response rates of 76%
were observed, with encouraging median OS of 19.3 months (95%
CI, 16.5-NR). These results are consistent with those observed in a
single centre US study [8]. This approach is currently under
investigation in the global KEYNOTE-811 trial. In contrast, the
results of the global LEAP-005 study of lenvatinib and pembro-
lizumab in previously treated gastric cancer presented at ASCO-GI
2021 were markedly different from those presented previously in
a single centre Japanese study [9, 10]. In the latter, radiological RR
of 69% (95% CI, 49–85) were reported, whereas in the global LEAP-
005 trial the objective RR was <10%, highlighting the importance
of international trials evaluating the efficacy of new drugs for
gastric cancer patients. Finally, updated results of the JACCRO-07
study were presented. These confirmed not just a recurrence-free
survival benefit but also an overall survival benefit for the addition
of docetaxel to adjuvant S1 chemotherapy [11]. This validates
docetaxel-S1 as a therapeutic option for resected gastric cancer in
Asian patients.
Overall, although the findings at GI ASCO were not practice
changing for patients with advanced oesophagogastric cancer,
they do offer hope for the development of effective therapies in
future. Whether targeted therapies such as anti-HER2 or anti-
FGFR2b will be combined with immune checkpoint blockade is
the emergent critical question.
HIGHLIGHTS IN HEPATOCELLULAR CARCINOMA, BILIARY
TRACT CANCER, NEUROENDOCRINE TUMOURS AND
PANCREATIC CANCER
EORTC hepatobiliary, pancreas and NET task force: Juan W.
Valle, Manfred P. Lutz and Jens Ricke
Cholangiocarcinoma (CCA). Dr Zhu presented the final OS results
of the randomised phase III ClarIDHy study wherein 187 patients
with previously treated isocitrate dehydrogenase-1-mutated
(mIDH1) CCA received either ivosidenib (an oral inhibitor of
mIDH1, n= 126) or placebo (n= 61) [12]. The study had previously
met its primary endpoint, PFS: HR 0.37, 95% CI, 0.25–0.54, one-
sided p < 0.0001] [13]. OS, a secondary endpoint, was confounded
by protocol-enabled cross-over to ivosidenib of placebo-treated
patients on disease progression, occurring with 43/61 (70.5%) of
patients. The final unadjusted median OS (mOS) was 10.3 vs.
7.5 months, HR 0.79, 95% CI, 0.56–1.12, one-sided p= 0.093;
however after pre-specified adjustment for cross-over (using the
rank-preserving structural failure time model), the mOS was 10.3
vs. 5.1 months, HR 0.49, 95% CI, 0.34–0.70, one-sided p < 0.0001.
The treatment had a tolerable safety profile and patients receiving
ivosidenib had preserved physical functioning and improved pain
scores on QoL measures. IDH1 mutation are found in 13% of
intrahepatic cholangiocarcinoma.
Dr Javle presented the final results of the phase II study of oral
infigratinib (BGJ398) in patients with previously treated CCA
harboring fibroblast growth factor receptor-2 (FGFR2) fusions and
rearrangements. These activating translocation events are found
in 20% of intrahepatic cholangiocarcinomas. This was deemed to
be an active regimen with a centrally confirmed RR of 23.1% (95%
CI, 15.6–32.2), median duration of response 5.0 months (95% CI,
0.9–19.1), PFS 7.3 months (95% CI, 5.6–7.6) and OS 12.2 months
(95% CI, 10.7–14.9); subgroup analysis suggested that less heavily
pre-treated patients (≤1 lines of treatment) derived greater
benefit. Although the commonest fusion partner was BBICC1,
35% of patients had a novel fusion partner. Adverse events
(mostly mechanism-based) were predominantly grade 1–2 and
manageable [14].
In her discussion, Dr Shroff highlighted the importance of
clinical benefit measures (e.g. impact on QoL) to patients in
addition to efficacy endpoints; and the emerging questions
around availability, optimal timing, selection (in the setting of
multiple agents), potential combinations, sequencing and identi-
fication of resistance mechanisms of targeted therapies in
cholangiocarcinoma, which she described as “the poster child
for precision medicine”.
Our understanding of cholangiocarcinoma pathogenesis makes
it, currently, the digestive cancer with the most numerous
























































































































Fig. 1 Progression-free survival and overall survival from the FIGHT trial: bemarituzumab plus mFOLFOX6 versus placebo plus
mFOLFOX6. Abstract 160 presented by Dr Z Wainberg at 2021 ASCO Gastrointestinal Cancers Symposium [3]. Reproduction with the
permission of the author.
T. Koessler et al.
2













and fusions should be systematically looked for as treatment
options are now available. Indeed, advanced cholangiocarcinoma
treatment landscapes evolve quickly with several new compounds
—almost all being tyrosine kinase inhibitors (TKI). As with other
TKIs, their effect is short-lived with rapid development of resistant
mutations. Treatment landscape is moving towards increasing the
duration of effectiveness of these compounds—by combining
TKIs with immune checkpoint inhibitors or with chemotherapy—
as well as developing a second generation of TKIs.
Hepatocellular carcinoma
IMBrave150 study survival update: The results of this first-line
study comparing atezolizumab and bevacizumab (atezo-bev) vs.
sorafenib have been published leading to the approval atezo-bev
for first-line treatment of advanced HCC [15]. At the time of the
publication, the mOS was “NR” vs. 13.2 months, HR 0.58, 95% CI,
0.42–0.79, p < 0.001, in favour of atezo-bev. With an additional
12 months of follow-up (median duration of follow-up
15.6 months) the mOS is 19.2 vs. 13.4 months, HR 0.66, 95% CI,
0.52–0.85, p= 0.0009, with early and sustained separation of the
survival curves, Fig. 2. Updated PFS is 6.9 vs. 4.3 months HR 0.65,
95% CI, 0.53–0.81, p= 0.0001; the response rate in atezo-bev-
treated patients was 30% including 8% complete responses
(RECIST) [16].
KEYNOTE-240 update: With an additional 18 months of follow-
up of the previously-reported study (median 40 months follow-
up), the updated OS was numerically maintained (and very similar)
in patients receiving pembrolizumab (vs. placebo, in second-line
for sorafenib-treated patients with advanced HCC): 13.9 vs.
10.6 months (HR 0.77, 95% CI, 0.62–0.96, p= 0.0112) [17]. The
PFS was also maintained: 3.3 vs. 2.8 months (HR 0.70, 95% CI,
0.56–0.89, p= 0.0011) with a superior RR (18.3% vs. 4.4% with
placebo) [18].
CheckMate-040 update: Four cycles of 3-weekly nivolumab
1mg/kg and ipilimumab 3mg/kg followed by 2-weekly nivolumab
240mg was approved in the USA for patients with disease
progression after sorafenib based on a RR of 32% (95% CI,
20–47%, RECIST v1.1) and OS 22.8 months (95% CI, 9.4–NR) [19].
With long-term follow-up (median 46.5 months), this activity is
maintained with RR 32% (95% CI, 20–47%, unchanged) with
duration of response 17.5 months (95% CI, 8.3–NR); OS
22.2 months (95% CI, 9.4–NR); and 3-year survival 42%. No new
safety signals were seen [20].
TACTICS study (TACE+ sorafenib vs. TACE alone) update: A co-
primary endpoint for this study (PFS) has previously been
published: 25.2 vs. 13.5 months in favour of the combination
(HR 0.59, p= 0.006) [21]. Results of OS, the other co-primary
endpoint, were presented. With a median follow-up of
33.4 months, the median OS was 36.2 (combination) vs.
30.8 months (TACE alone); HR 0.86, 95% CI, 0.61–1.22, p= 0.40.
A greater proportion of patients randomised to TACE alone
received subsequent therapies (76.3% compared to 58.8%) which
potentially confounded the OS analysis as the PFS remained
statistically significantly in favour of the combination. The authors
argued that OS is no longer an appropriate endpoint for TACE-
based studies [22].
In conclusion, immune checkpoint inhibition is now part of the
advanced hepatocellular carcinoma treatment landscape, its role
in earlier settings such as post resection or in association with local
treatments is heavily studied. In advanced disease, the importance
of the sequence now becomes critical, bearing in mind that 40%
of patients will not be able to have a second line of treatment, and
in light of the recent analysis published by Pfister et al. showing
that hepatocellular carcinoma of non-alcoholic steatohepatitis
origin might be less responsive to immunotherapy [23].
Neuroendocrine tumours (NET). The results of the phase II/III
AXINET study were presented by Dr Garcia-Carbonero. Patients
(n= 256) with pre-treated (≤2 lines of prior therapy), progressive,
well-differentiated grade (G)1–2 extra-pancreatic NETs were
randomised (1:1, stratified by time from diagnosis, gastrointestinal
vs. non-gastrointestinal and by Ki67 ≤ 5% vs. >5%) to receive
octreotide LAR with either oral axitinib (a potent VEGFR1–3
inhibitor) or placebo. The primary endpoint was not met: median
investigator-assessed PFS 17.2 vs. 12.3 months (HR 0.82, 95% CI,
0.61–1.09, p= 0.0169), although patients receiving axitinib has a
superior radiological response rate (17.5% vs. 3.8%, p= 0.0004).
Blinded independent central review is ongoing. The safety profile
was as expected from axitinib in other indications. Exploratory
subgroup analysis suggests that patients with G1 NETs may derive
greater benefit [24]. The discussant (Dr Snyder) advised caution in
interpreting the G1 subgroup due to the small size of the
subgroup (n= 22). She also set the results in context with other
available therapies, primarily peptide receptor radionuclide
therapy and everolimus, and highlighted that the role of multi-
targeted tyrosine kinase inhibitors in these patients remains an
active area of investigation.
Peptide receptor radionuclide therapy (PRRT) with Lu 177-
dotatate is standard of care for well-differentiated (WD) NETs
following progression on somatostatin analogues. Das et al, build
a clinical score predicting outcome for patients with WD NETs
receiving PPRT. The clinical score includes 5 variables: available
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Fig. 2 Updated overall survival data from the IMbrave150 study: atezolizumab+ bevacizumab versus sorafenib in patients with
unresectable hepatocellular carcinoma. Abstract 267 presented by Dr R Finn at 2021 ASCO Gastrointestinal Cancers Symposium [16].
Reproduction with the permission of the author.
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patient symptoms, tumour burden in critical organs and
peritoneal carcinomatosis presence each variable being score
from 0 to 2 except peritoneal carcinomatosis from 0 to 1. For each
2-point increase in clinical score, the estimated HR for PFS is 3.26
(95% CI, 2.05–5.19) [25]. Coffman et al shared their experience on
PRRT in WD high grade (HG), average tumour Ki67: 34.8% NETs
with 63% partial response, 6% stable disease and 31% progressive
disease amongst 19 treated patients [26].
Al-Toubah et al. treated 34 patients with HG neuroendocrine
neoplasms with dual checkpoint inhibitor therapy—anti-PD-1 and
anti-CTLA-4. Most patients (79.4%) had poorly differentiated NECs
and 20.6% had WD HG NETs. With ORR: 14.7%, DCR: 41.2% and
median PFS: 1 month, dual checkpoint inhibitor therapy has
modest activity in HG, pre-treated neuroendocrine neoplasms
[27]. In the PLANET, phase Ib/II trial, pembrolizumab and
lanreotide were administered at 22 patients having progressed
on somatostatin analogues. No response was observed, 40%
had partial response and 50% progressive disease. Median PFS
was 5.4 months and median OS not reached at 15 months of
follow-up [28].
To conclude in the field of WD NETs, PRRT is a corner stone, and
its effectiveness can now be predicted with clinical score. PRRT is
currently being combined with chemotherapy or immunotherapy
in different trials. Results on PRRT using somatostatin antagonist
either for diagnostic or for therapeutics (e.g. 177Lu-OPS201) is
eagerly awaited. Currently immunotherapy plays no role; however,
it might change judging by the 40% partial response in the
PLANET trial.
Pancreatic cancer. Neoadjuvant treatment of borderline resect-
able pancreatic adenocarcinoma is increasingly used worldwide
and has even become part of the recommended standard
treatment approach in the United States (NCCN 2020). The
Alliance A021501 phase II trial was designed to select a reference
regimen for future trials. Chemotherapy with mFOLFIRINOX (8
cycles) with or without radiotherapy (mostly SBRT, up to 40 Gy in 5
fractions) before surgery and adjuvant FOLFOX 6 (4 cycles) were
evaluated in comparison to historical controls. The SBRT arm had
to be closed after a planned interim analysis because of a poor R0
resection rate of only 25%. In the mFOLFIRINOX arm (n= 70), the
R0 resection rate reached 42%, with a median OS of 31 months.
The 18 months survival rate of 66.4% compares favourably with
the pre-specified rate in historical controls of 50%, reinforcing
mFOLFIRINOX as the reference for future trials [29].
In advanced disease, the PARP inhibitor olaparib has already
been introduced as optional maintenance treatment by the POLO
phase III trial, at least for patients with germline BRCA mutations
and after disease stabilisation under platinum-based therapy [30].
The updated final overall survival analysis confirmed that OS was
similar in the olaparib and placebo arm (19.0 vs. 19.2 months),
with HR 0.83, 95% CI, 0,56–1,22, p= 0.349 [31]. The main benefit of
olaparib was a strong trend in PFS2 (16.9 vs. 9.3 months, HR 0.66,
95% CI 0,43–1.02, p= 0.061), which is driven by long-term effects
in the olaparib arm (rate of survival without progression after
36 months of 31.2% with olaparib vs. 13.1% for placebo). These
results seem to be independent from the type of BRCA mutation
and are also valid when the primary tumour—and not the
metastases—are used as target lesion [32, 33].
Several groups presented feasibility data for cfDNA measure-
ments. Tumour mutation burden (TMB) could be analyzed in 173/
174 (99.4%) plasma samples of the PA.7 trial, which examined the
efficacy of combined PD-L1 and CTLA-4 inhibition with gemcita-
bine and Nab-paclitaxel [34]. Only one patient was MSI-H with a
TMB of 52.9 muts/Mb. Cut-point analysis defined ≥ 9 muts/Mb
(4.6% of the patients) as predictive for increased OS with
combined checkpoint inhibition. In another retrospective analysis,
comprehensive genomic profiling of cfDNA detected at least one
somatic alteration in 613/1009 (60.8%) of the examined samples
[35]. Most common were gene alterations in TP53 (53.7%), KRAS
(40.3%), CDKN2a (6.5%), and in genes of the homologous
recombinant DNA damage repair pathway (HR-DDR) in 12.3%. In
addition, serial measurements with clearance of mTP53 or mKRAS
cfDNA seemed to be predictive of increased PFS (HR 0.087
and 0.32 with p= 0.0056 and p= 0.037, respectively) in a
small retrospective analysis of 23 patients under systemic
treatment [36].
To conclude, in locally advanced and borderline pancreatic
cancer, neoadjuvant chemotherapy is now clearly recommended.
Chemotherapy choice encompasses FOLFIRINOX, mFOLFIRINOX or
gemcitabine and albumin-bound paclitaxel. The benefit of PARP
inhibitor, Olaparib, is confirmed in PFS in patients with germline
BRCA mutations; however, the lack of survival and quality of life
benefit should push clinicians to weigh the risk/benefit carefully.
HIGHLIGHTS IN ANAL AND LOCALISED COLORECTAL CANCER
EORTC anal and localised colorectal cancer task force: Dirk
Arnold and Lucjan Wyrwicz
Previously, two independent studies showed the equal efficacy of
short course radiotherapy and chemoradiation in locally advanced
rectal cancer. There is the issue of excessive mortality in treatment
of frail and elderly patients who undergo total mesorectal excision
(TME). NACRE study presented by Eric Francois et al. focused only
on elderly patients (>74 years old) randomising them to either
short course RT or chemoradiation. Oncological outcomes were
similar in both groups, with well-defined trends in 6- and 12-
months excessive deaths in the chemoradiation arm (10% vs 3.9%
at 6 months: 12% vs 3.9% at 12 months), Fig. 3. This observation
should be verified in other datasets but can be applied especially
in the case of frail elderly patients [37].
An important clinical question is whether patients with less
advanced rectal cancer can undergo treatment and have a
substantial chance of true organ preservation (i.e. watch-and-wait
approach or local excision without TME). The preliminary out-
comes of OPERA study presented by Sun Myint A. et al. has shown
an organ preservation rate of more than 80% in cT2/T3 N0/1
patients treated with either chemoradiation (45 Gy) with addi-
tional external beam boost (9 Gy) or contact X-ray brachytherapy
(90 Gy). Blinded combined outcomes of both arms were presented
with only 19.4% patients who needed TME surgery throughout the
observation period [38].
The major trend observed in rectal cancer is associated with a
broad implementation of total neoadjuvant therapy (TNT) into
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Fig. 3 Overall survival from the NACRE trial: short course
radiotherapy versus radiochemotherapy for locally advanced
rectal cancers in the elderly. Abstract 4 presented by Dr E François
at 2021 ASCO Gastrointestinal Cancers Symposium [37]. Reproduc-
tion with the permission of the author.
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covering different aspects of early chemotherapy in the treatment
of rectal cancer. Osama Rahma et al. presented the results of the
pembrolizumab arm from NRG-GI002 platform. NRG-GI002 is a
basket study utilising a neoadjuvant score for assessment of
activity of novel compounds in TNT. Despite a favourable toxicity
profile, pembrolizumab added to neoadjuvant chemoradiation
has not improved the early outcomes of locally advanced rectal
cancer patients [39].
In conclusion, the definition of “new standards of care” in locally
advanced rectal cancer and anal cancer is ongoing: It is clear now
that many treatment modalities may be subject to decision
making by clinical factors as well as radiographic assessment, and
a large armamentarium of (situation dependend) “best options”
are available, also in consideration of the treatment goals.
However, the role of newer decision factors—mostly from biologic
factors—is still matter of investigation.
HIGHLIGHTS IN METASTATIC COLORECTAL CANCER
EORTC metastatic colorectal cancer task force: Thibaud
Kössler, Francesco Sclafani, Mark Peeters
The KEYNOTE-177 is a randomised phase III trial comparing
pembrolizumab (anti-PD-1) to chemotherapy in MSI-High/dMMR
metastatic CRC (mCRC) in first line. Pembrolizumab showed
improvement in progression-free survival (PFS, co-primary out-
come) (median, 16.5 vs. 8.2 months; HR 0.60; 95% CI, 0.45–0.80,
P= 0.0002, overall RR: complete and partial, 43.8% vs. 33.1% and ≥
grade 3 treatment-related adverse events (TRAEs) (22% vs. 66%)
[40]. At ASCO-GI 2021, the PFS2 (PFS on next line of therapy or
death from any cause) was presented and also favoured
pembrolizumab (NR vs. 23.5 months; HR 0.63, 95% CI, 0.45–0.88),
Fig. 4. Quality of life was also significantly improved in the
immunotherapy arm using the EORTC QLQ -C30 scale [41]. OS, the
second co-primary outcome, are expected in 2021. These results
confirm pembrolizumab as standard of care, for first-line treat-
ment in MSI-High/dMMR mCRC.
he GARNET trial is testing dostarlimab (anti-PD-1) in a multi-
cohort trial. This year the non-endometrial dMMR/MSI-H pan
tumour cohort was presented. Primary objectives were ORR and
duration of response (DOR). Amongst 99 patients recruited, ORR
was 38.7% (95% CI, 29.4–48.6) with complete response in 7.5%.
The median DOR was not reached and grade ≥ 3 TRAEs were 8%.
Within the 69 (65%) mCRC enrolled, ORR was 36.2%, matching the
results of other anti-PD-1 antibodies (nivolumab and pembrolizu-
mab) in pre-treated dMMR/MSI-H mCRC [42–44]. These results
confirm the activity of anti-PD-1 antibodies in pre-treated MSI-
High/dMMR mCRC.
Preclinical data have shown that anti-EGFR therapy (e.g.
panitumumab or cetuximab) causes tumour-specific adaptive
immune response and immunogenic apoptosis, with functional
adaptive immunity required to mediate efficacy [45]. Anti-EGFR
antibody therapy is associated with increased expression of CTLA-
4 and PD-L1 [46]. The LCCC1632 trial, hypothesised that addition
of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) to panitu-
mumab increases response rate (at 12 weeks) in pre-treated
patients with KRAS/NRAS/BRAFWT MSS mCRC. The trial enrolled 56
patients; out of the 49 evaluable subjects, the 12-week RR was
35% (95% CI, 21–48) with no complete response, median PFS was
5.7 months (95% CI, 5.5–7.9) and median OS was 27 months (95%
CI, 14.5-NR) [47]. These results show no advantage over anti-EGFR
treatment alone [48].
The TASCO1 study is a phase II randomised open-label
noncomparative study assessing safety and efficacy (PFS, primary
outcome) of first-line treatment with trifluridine/tipiracil plus
bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in
untreated patients with mCRC not candidates for standard
oxaliplatin- or irinotecan-based chemotherapy regimens. Median
PFS was 9.2 (95% CI, 7.6–11.6) and 7.8 (95% CI, 5.5–10.1) months in
the TT-B and C-B groups, respectively [49]. At ASCO-GI 2021,
authors presented the median OS which was 22.31 months in TT-B
and 17.67 months in C-B with HR 0.78 (95% CI, 0.5–1.10). Survival
probability at 18 months in TT-B was 62% (95% CI, 50–72%), and
47% (95% CI, 35–57%) in C-B [50]. TT-B treatment shows clinical
activity in untreated patients with unresectable mCRC ineligible
for intensive therapy.
In conclusion, MSI-H/dMMR mCRC patients should receive
immune checkpoint inhibitors as first (preferably) or later lines
of treatment. One of the burning questions is how to select those
who will respond to single-agent immune checkpoint inhibition
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Fig. 4 Time from randomisation to progression on next line of therapy (PFS2) from the KEYNOTE-177 trial: Pembrolizumab versus
chemotherapy for microsatellite instability-high advanced colorectal cancer. Abstract 6 presented by Dr K-K Shiu at 2021 ASCO
Gastrointestinal Cancers Symposium [41]. Reproduction with the permission of the author.
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combination of anti-PD-1+ anti-CTLA-4 likely improving out-
comes as suggested by the single-arm CheckMate-142 study) or
standard chemotherapy. Furthermore, future research efforts
should be largely directed to the investigation of alternative
treatment strategies that could extend the benefit of immu-
notherapy to the by far larger group of inherently immune-
resistant MSI-H/dMMR mCRC patients.
HIGHLIGHTS IN EARLY PHASE TRIALS
EORTC early phase trials task force: Radka Obermannova and
Maria Alsina
Several new initiated early phase studies and phase 3 combina-
tions of target therapies were presented at the congress. The
following account provides an overview of selected trials in
progress investigating new molecules, especially target treatment
and immunotherapy combinations.
In HER2 positive disease, phase II/III study MOUNTAINEER-02
investigates tucatinib, trastuzumab, ramucirumab and paclitaxel in
previously treated HER2-positive gastric or gastroesophageal
junction adenocarcinoma (GEC). Tucatinib is a highly selective
HER2-directed TKI. Since phase 2 will establish a recommended
dose of combination, phase 3 aims to compare the efficacy and
safety of tucatinib plus trastuzumab (Arm 3 A; 235 patients) vs.
placebo (Arm 3B;235 patients), both in combination with
ramucirumab and paclitaxel, and also evaluate the activity of
tucatinib, ramucirumab, and paclitaxel (Arm 3 C; 30 patients). The
dual primary phase 3 endpoints are OS and PFS [51].
DESTINY-Gastric03 is a phase Ib/II, dose-escalation, and dose-
expansion study that evaluates trastuzumab deruxtecan (T-DXd,
DS-8201) monotherapy and combinations with chemotherapy or
±checkpoint inhibitor in patients with HER2-overexpressing
gastric cancer. In part 2, the stratification according to
HER2 status will be provided (NCT04379596). Finally, an ongoing
study with margetuximab combined with anti-PD-1 (retifanlimab)
or anti-PD-1/LAG-3 (tebotelimab) ± chemotherapy in first-line
therapy of advanced/metastatic HER2+ gastroesophageal junc-
tion (GEJ) or gastric cancer (GC) deserves mention [52].
Checkpoint inhibitors showed modest activity in unselected
population in gastric cancer. NCT04164979 is the prospective,
phase 2 trial investigating if cabozantinib contributes to over-
coming primary or secondary resistance to PD-1 blockade in GEC.
Patients previously treated with fluoropyrimidine/platinum and a
prior checkpoint inhibitor if tumour PD-L1 CPS ≥ 10% are assigned
to cabozantinib plus pembrolizumab. The primary objective is
determining the feasibility of the combination and estimating its
efficacy [53].
Another phase II/III study focuses on the treatment selected
based on new predictors. Cohort 3 of the Phase II ILUSTRO study
evaluates zolbetuximab, a chimeric IgG1 monoclonal antibody,
against CLDN18.2 in combination with pembrolizumab in claudin
18.2 positive locally advanced or metastatic gastric or gastro-
esophageal junction adenocarcinoma with the hypothesis that
this combination might augment ADCC and antitumour immune
response in CLDN18.2 overexpressing cancers. The primary
endpoint is the objective response rate (NCT03505320) [54].
NCT03207347 is a phase II, multicenter study aiming to exploit
the concept of synthetic lethality using the PARP inhibitor
niraparib in patients with metastatic relapsed refractory solid
tumours. Cohort A includes tumours harboring suspected BAP1
mutations (in terms of histology, including cholangiocarcinoma,
uveal melanoma, mesothelioma or clear cell renal cell carcinoma)
with tissue available for BAP1 mutational assessment via NGS or
Cohort B (histology-agnostic): tumours with known DNA damage
response (DDR) mutations confirmed by CLIA-approved NGS [55].
NCT04515394 is a phase II study in patients with advanced left-
sided RAS/BRAF wild-type colorectal cancer. This study aims to
explore tepotinib plus cetuximab in patients with acquired
resistance to anti-EGFR antibody therapy due to MET amplifica-
tion. Tepotinib is an oral, highly selective, potent MET tyrosine
kinase inhibitor. The primary endpoint is an investigator-assessed
objective response [56].
And finally, the last selected study is SWOG S2001, a
randomised phase II trial exploring maintenance olaparib mono-
therapy versus olaparib plus pembrolizumab in metastatic
pancreatic cancer patients with germline BRCA 1 or BRCA 2
mutations who did not progress on first-line platinum-based
chemotherapy. The primary endpoint is to reach mPFS of
11.7 months in the experimental arm (NCT04548752) [57].
In conclusion, based on known predictors, in HER2 positive
metastatic GC, results from trials of trastuzumab deruxtecan, and
similarly, margetuximab, in combination with checkpoint inhibi-
tors should evaluated in the light of results from ongoing phase III
KEYNOTE-811 trial (NCT03615326) that is focusing on trastuzumab
and pembrolizumab combination, and then phase II INTEGA trial,
exploring the combination of nivolumab and trastuzumab or
chemotherapy plus ipilimumab (AIO STO 0217). Zolbetuximab
plus checkpoint inhibitor in claudin 18.2 population will show if
augments antitumour immune response and ADCC. And finally,
tepotinib in combination with cetuximab could be a promising
new target therapy in RAS wt CRC with acquired resistence to anti-
EGFR therapy.
HIGHLIGHTS IN ADOLESCENT AND YOUNG ADULTS
EORTC adolescent and young adults task force: Irit Ben-
Aharon
Early-onset colorectal cancer (EOCRC) represents a major clinical
and health-policy challenge due to its rising incidence in the
Western world in the past decade. A study performed by the
Colorectal Cancer Alliance addressed the results of an online
survey of EOCRC patients and survivors (<50 y) in the US, which
was designated to capture their self-reported experiences using
several quality-of-life validated tools [58]. Among 1089 partici-
pants, the majority were female and Caucasian. Most respondents
(62%) waited 3–12 months before seeking medical advice, and
most indicated they were initially misdiagnosed or referred to
multiple doctors prior to cancer diagnosis. African-Americans were
four times more likely to report poor health compared with
Caucasian respondents. Asian Pacific and Hispanic-Latino reported
favourable prior health status. More than 77% of the respondents
were diagnosed at stage 3 or 4 disease. These results imply
multiple challenges in the primary care of young patients
diagnosed with CRC manifested by a delayed path to diagnosis
and subsequently advanced stage at diagnosis. Another study
evaluated racial disparities among EOCRC compared with older-
onset [59]. Colorectal cancer patient data were retrieved from the
National Cancer Database (NCD) and analyzed upon age and other
sociodemographic parameters. The study population comprised
1,061,204 patients, 10.2% were EOCRC. Compared to older
patients, EOCRC patients were more likely to be African-
American or Hispanic and to be diagnosed with metastatic
disease. Young patients had improved survival over older patients
(median OS 157.4 months compared with 64.2 months).
Upper gastrointestinal cancers such as esophageal and gastric
cancer are on the rise, while there is a paucity of data regarding
the disease of early-onset esophagogastric cancer (EOEGC). A
retrospective study evaluated clinical features and molecular
landscape of EOEGC compared with average-onset and revealed
data on 151 EOEGC (<49 y) and 587 average-onset patients [60].
Time to diagnosis was longer in EOEGC, though stage did not
differ. Signet cell histology was more common in EOEGC. A trend
toward higher MSI-High status in average-onset was demon-
strated. Another study addressed socioeconomic and pathologic
characteristics of EOEGC in the NCD and revealed that EOEGC
(defined < 60 y) tend to be African-American or Hispanic and to
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have an advanced disease at presentation [61]. An optimistic note
with regard to early-onset pancreatic cancer (EOPC) derives from a
study which appraised clinical characteristics of EOPC (<60 y)
retrieved from the NCD and compared to average-onset. EOPC
patients had higher median OS, though they were more likely to
be diagnosed with metastatic disease [62].
In conclusion, as the incidence of early-onset GI cancers is rising,
elucidating epidemiological and biological perspectives is key for
early detection and treatment tailoring. Studies presented herein
which addressed self-reported experiences of EOCRC patients
revealed a delayed course to diagnosis and subsequently late
stage, as well as racial disparities that was also demonstrated in
early-onset gastric cancer. An optimistic view reflected by current
data indicating that survival of early-onset GI cancer patients is not
inferior to average-onset patients.
CONCLUSION
EORTC Gastrointestinal Tract Cancer Group: Markus Moehler
(Group Chairman) and Elisa Fontana (Group Secretary)
Significant efforts to find effective treatment options aimed at
improving survival outcomes in gastrointestinal cancer continue,
despite the COVID-19 pandemic. Drug development and clinical
trial machinery should not stop; similarly, reporting clinical trial
results and sharing details of trials in progress with the research
community is crucial. Switching to virtual meetings may possibly
have had an impact on conference attendance, the exchange of
ideas, and interactions between academic researchers and
pharmacompanies. Attendance at key events should be encour-
aged and facilitated; with this manuscript we want to support the
divulging of new scientific findings presented in a key conference
for physicians treating gastrointestinal cancers.
The importance of targeting key molecular events like HER2
overexpression or FGFR gene alteration is once again highlighted
in this conference. Adding targeted agents to the backbone of
chemotherapy regimens in early lines seems feasible although
possibly challenged by biomarker testing; turnaround time and
tissue availability need to be taken into account as soon as
possible for timely clinical trial inclusion. Chemo-free approaches
are more frequently explored; single-agent activity of FGFR
inhibitors is well known in upper GI and biliary track cancers.
The development of new-generation anti-HER2 agents like
margetuximab and zanidatamab, with proven single-agent
activity, may expand chemo-free opportunities also in HER2
positive cancers.
Immune checkpoint inhibitor (CPI) activity continues to be
explored in combination with chemotherapy and targeted agents
or in chemo-free regimens, with interesting results in upper GI and
hepatobiliary cancers. In colorectal cancer, the significant impact
of CPIs in microsatellite instable cancers was once again confirmed
in both first-line and chemorefractory setting; conversely, another
attempt to switch cold microsatellite stable CRC into hot tumours
was disappointing.
In line with global efforts, within our GI Task Forces several
ongoing trials are exploring HER2-targeted and CPIs approaches.
The INNOVATION trial is exploring whether adding trastuzumab or
trastuzumab and pertuzumab to chemotherapy increases the
pathological response rate in HER2 positive gastric or gastro-
esophageal adenocarcinomas (NCT02205047). The adjuvant VES-
TIGE trial is investigating nivolumab plus ipilimumab versus
standard post-operative chemotherapy in gastroesophageal
adenocarcinoma patients with high risk of disease recurrence
(NCT03443856). The ABC-09 trial is an open-label single-arm trial
of pembrolizumab plus standard first-line chemotherapy in biliary
track cancers (NCT03260712). The ILOC trial is a phase II trial of
durvalumab plus local tumour ablation in patients with colorectal
liver metastases (NCT03101475).
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